RNA Biomarker Company Genialis Attends BIO Asia to Grow Collaborations in Taiwan
Company looks to expand partnerships and presence across Asia [...]
Cell therapy for T-cell malignancies—the science and business of developing curative medicines for patients in need | TPM podcast #37
Genialis’ Upcoming Events Genialis™ krasID [...]
Pharma Oncology Development Veteran Krista McKerracher Named Chairperson of the Board for Genialis
With a career dedicated to delivering firsts in medicine [...]
Genialis and Pancreatic Cancer Action Network (PanCAN) Partner to Progress KRAS Diagnostics
PanCAN’s Know Your Tumor precision medicine service will be [...]
Tackling healthcare disparities and bridging the digital divide: it doesn’t have to be so hard | TPM podcast #36
Genialis’ Upcoming Events Genialis™ krasID [...]
KRAS Drug Market and the Biomarker Opportunity
Highlights Mutated RAS genes have been known significant [...]
The Science and Art of De-risking Cancer Drug Development | TPM podcast #35
Genialis™ krasID New Genialis RNA Biomarker [...]
New Genialis RNA Biomarker Accurately Predicts KRAS Outcomes in Lung Cancer Patients
Poster at AACR 2024 shows Genialis™ krasID biomarkers can [...]
Genialis™ krasID: Biology-Driven Machine Learning to Personalize KRAS Inhibitor Therapy
Genialis krasID analyzes foundational aspects of KRAS biology using RNA-sequencing [...]
Genialis Enlists Two New Partners as It Assembles World’s Most Ethno-Geographically Diverse Cancer Data Sets
The addition of data from Sidra Medicine and Sapien [...]
